NLST

Hummingbird Diagnostics Announces Publication of miLung Small RNA-Based Blood Test for Early Detection of Lung Cancer in the Journal of Thoracic Oncology

Retrieved on: 
Tuesday, July 11, 2023

Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic Oncology following a poster presentation at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection.

Key Points: 
  • Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic Oncology following a poster presentation at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection.
  • Screening was performed on stabilized whole blood samples from 1,384 individuals meeting National Lung Screening Trial (NLST) lung cancer eligibility criteria (age 55-74, pack-years ≥30) by leveraging ultra-deep small RNA sequencing.
  • The miLung small RNA blood test is noninvasive and identifies specific small RNAs, molecular biomarkers associated with lung cancer in whole blood samples that can be drawn at the point of care.
  • “Early cancer detection remains the most effective strategy to reduce mortality associated with lung cancer,” commented Jochen Kohlhaas, Founder and Chief Executive Officer of Hummingbird Diagnostics.

How do we know health screening programmes work?

Retrieved on: 
Friday, June 30, 2023

Barclay’s figure is no doubt correct, but is it the right statistic to use to justify the screening programme?

Key Points: 
  • Barclay’s figure is no doubt correct, but is it the right statistic to use to justify the screening programme?
  • The latter is known as “lead-time bias”, and can mean that statistics like five-year survival rates paint a misleading picture of how effective a screening programme really is.
  • Without a screening programme, greyness may not be spotted until enough grey hairs have sprouted to be visible without close inspection.
  • Despite their post-diagnosis life expectancy being longer, the early diagnosis has done nothing to alter their life expectancy.

Overdiagnosis

    • Screening can also lead to the phenomenon of overdiagnosis.
    • Still, the C-word induces such mortal fear in most people that many will, often on medical advice, undergo painful treatment or invasive surgery unnecessarily.
    • So, what statistics should we be using to measure the effectiveness of a screening programme?
    • The answer is to look at mortality rates (the proportion of people who die from the disease) in a randomised controlled trial.

NETLIST WINS $303 MILLION IN PATENT INFRINGEMENT TRIAL AGAINST SAMSUNG

Retrieved on: 
Monday, April 24, 2023

IRVINE, Calif., April 24, 2023 /PRNewswire/ -- Netlist, Inc. (OTCQB: NLST) today announced that it won a $303 million damages award against Samsung Electronics Co., Ltd., Samsung Semiconductor, Inc., and Samsung Electronics America, Inc. (together "Samsung") in the United States District Court for the Eastern District of Texas.  The award resulted from a jury trial that lasted six days, and involved five Netlist patents: U.S. Patent Nos. 10,949,339, 11,016,918, 11,232,054, 8,787,060, and 9,318,160.  The products found to infringe these patents were all Samsung DDR4 LRDIMM, DDR5 UDIMM, SODIMM, and RDIMM, and high bandwidth memory (HBM) 2, 2E and 3 components.

Key Points: 
  • IRVINE, Calif., April 24, 2023 /PRNewswire/ -- Netlist, Inc. (OTCQB: NLST) today announced that it won a $303 million damages award against Samsung Electronics Co., Ltd., Samsung Semiconductor, Inc., and Samsung Electronics America, Inc. (together "Samsung") in the United States District Court for the Eastern District of Texas.
  • The award resulted from a jury trial that lasted six days, and involved five Netlist patents: U.S. Patent Nos.
  • The conclusion of Netlist's 16-month-long case against Samsung (Netlist, Inc. v. Samsung Electronics Co. Ltd., et.
  • The amount of damages awarded by the jury covers infringement by Samsung through March 2023.

Andrea McKee, M.D. and the late Brady McKee, M.D. to be honored with the James L. Mulshine, M.D., National Leadership Award for ensuring equitable access to high quality lung cancer screenings

Retrieved on: 
Tuesday, November 1, 2022

will be honored with the James L. Mulshine, M.D., National Leadership Award on Thursday, November 3 at the Prevent Cancer Foundations 19thannual Quantitative Imaging Workshop.

Key Points: 
  • will be honored with the James L. Mulshine, M.D., National Leadership Award on Thursday, November 3 at the Prevent Cancer Foundations 19thannual Quantitative Imaging Workshop.
  • Dr. Andrea McKee will accept the award on behalf of herself and her late husband for their contributions to ensuring community hospitals and cancer centers provide equitable access to the highest quality screenings.
  • Andrea and Brady McKee were instrumental in developing the LungRADS system, a quality assurance tool to standardize lung cancer screening reporting and management recommendations, reduce confusion in lung cancer screening interpretations and facilitate outcome monitoring.
  • They also conducted critical studies demonstrating that high quality screening is possible in a varietyof health care delivery institutions.

DGAP-News: A Quick Look at the OTC Markets' Most-Active Securities In August - Here’s What You Need to Know

Retrieved on: 
Tuesday, September 13, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 4.08% in August, its fifth month of decline in 2022.

Key Points: 
  • The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 4.08% in August, its fifth month of decline in 2022.
  • Additionally, two Ethereum-based securities found themselves in improved positions on the OTCQX Best Markets Most Active list.
  • The OTCQX Best Market recorded $7 billion in trades in August, a figure that has been relatively unchanged since July.
  • Below are the top 10 most actively traded securities on the OTCQX Best Market and OTCQB Venture Market in August.

NELSON Trial Protocol More Sensitive than NLST and May Increase the Benefits of Lung Cancer Screening, While Reducing Unnecessary Follow-up Procedures

Retrieved on: 
Sunday, August 7, 2022

VIENNA, Aug. 7, 2022 /PRNewswire-PRWeb/ -- The protocol used to screen and detect lung cancer in the NELSON Trial is more sensitive than the protocol used in the National Lung Cancer Screening Trial, particularly for early-stage cancers, according to research reported today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

Key Points: 
  • The protocol used to screen and detect lung cancer in the NELSON Trial is more sensitive than the protocol used in the National Lung Cancer Screening Trial, particularly for early-stage cancers, according to research reported today at the IASLC World Conference on Lung Cancer 2022 in Vienna.
  • VIENNA, Aug. 7, 2022 /PRNewswire-PRWeb/ -- The protocol used to screen and detect lung cancer in the NELSON Trial is more sensitive than the protocol used in the National Lung Cancer Screening Trial, particularly for early-stage cancers, according to research reported today at the IASLC World Conference on Lung Cancer 2022 in Vienna.
  • The Dutch-Belgian lung cancer screening trial (Nederlands-Leuvens Longkanker Screenings Onderzoek [NELSON]) demonstrated a reduction in lung cancer mortality of 24% for screening with low-dose computed tomography (CT), compared to the 20% found in the National Lung Screening Trial.
  • Nodule management protocols based on volumetry are therefore likely to increase the benefits of lung cancer screening, while reducing unnecessary follow-up procedures.

CMS Assigns New Technology Payment Classification for Optellum's Lung Cancer Prediction Score

Retrieved on: 
Tuesday, June 28, 2022

HOUSTON and OXFORD, United Kingdom, June 28, 2022  /PRNewswire/ -- Optellum announced that the Centers for Medicare & Medicaid Services (CMS) has established a national payment rate for Optellum's Lung Cancer Prediction technology under the New Technology Ambulatory Payment Classification. This development will facilitate the process of health insurance claims for individuals enrolled in Medicare and other health insurance programs, enabling more patients to access innovative, potentially life-saving early lung cancer diagnostic technology.

Key Points: 
  • HOUSTON and OXFORD, United Kingdom, June 28, 2022 /PRNewswire/ -- Optellum announced that the Centers for Medicare & Medicaid Services (CMS) has established a national payment rate for Optellum's Lung Cancer Prediction technology under the New Technology Ambulatory Payment Classification.
  • "This is another step in Optellum's progress towards becoming the standard of care for early lung cancer diagnosis.
  • "This new payment assignment is an important step towards incentivizing providers to make the technology more widely available."
  • He has extensive experience in the application and translation of imaging research for evaluating lung nodules and lung cancer.

Median Technologies Announces Design Completion of its iBiopsy® Lung Cancer Screening End-to-end CADe/CADx Software as Medical Device (SaMD) with Outstanding Sensitivity & Specificity Performance

Retrieved on: 
Tuesday, March 22, 2022

Median Technologies (ALMDT:PA) announces outstanding performance of its iBiopsy LCS AI/ML tech-based end-to-end CADe/CADx Software as Medical Device, intended to enable early detection and characterization of lung cancer nodules and improve clinical management of patients.

Key Points: 
  • Median Technologies (ALMDT:PA) announces outstanding performance of its iBiopsy LCS AI/ML tech-based end-to-end CADe/CADx Software as Medical Device, intended to enable early detection and characterization of lung cancer nodules and improve clinical management of patients.
  • With this breakthrough innovation, Medians iBiopsy LCS SaMD brings a unique AI-powered solution for clinicians to fight lung cancer, the deadliest cancer worldwide.
  • Results released today show unrivalled performance for Medians end-to-end detection/diagnosis approach for lung cancer screening.
  • These results pave the way for a disruptive approach in lung cancer screening management, Fredrik Brag, CEO and founder of Median Technologies said.

Median Technologies Announces New Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 With a Focus on Stage 1 Lung Cancer Characterization

Retrieved on: 
Tuesday, November 23, 2021

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules.
  • New results specifically focus on the characterization of stage 1 lung cancer nodules, using Medians proprietary iBiopsy deep learning algorithm on low-dose chest computed tomography (LDCT).
  • Lung cancer is the number one cancer killer globally, causing an estimate of 1.8m deaths, accounting for 18% of all cancer deaths in 20202.
  • A noteworthy International Early Lung Cancer Action Program (I-ELCAP) cohort study of stage 1 cancer patients4 revealed an excellent 15-year LCS survival of 92% which again serves to show how critical early stage diagnosis via lung cancer screening remains.

Median Technologies Announces Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 to Accurately Characterize Malignant vs Benign Lung Nodules Based on a Large-scale Patient Cohort

Retrieved on: 
Monday, September 6, 2021

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.
  • The Median Technologies iBiopsy Lung Cancer Development Plan was launched in February 2021 , as part of the Companys strategic positioning in early-stage disease diagnosis.
  • Major international studies have shown that LDCT lung cancer screening can reduce mortality by 44% (NELSON Trial, 2018).
  • The study was based on a cohort of 1,696 patients from the National Lung Screening Trial cases (NLST) consisting of a total of 15,608 lung nodules.